Is MOTS-c Legal in Texas?
HealthRX.com
Federal rules give MOTS-c no standard compounding pathway
See the public record for MOTS-c
At a glance
- FDA approval / None; not part of any approved drug [1]
- Pharmacy and physician compounding status / In none of the three FDA categories for state-licensed pharmacies and physicians [2][4]
- Outsourcing facility status / Absent from FDA's outsourcing facility list [3]
- Safety-risk table / In FDA's 'nominated but withdrawn' table of substances flagged for possible significant safety risks [7]
- HHS draft policy / Filed October 28, 2026; non-binding; acetate injection only [5][6]
- Human data / No published study giving MOTS-c to a person [1]
- Sport / WADA prohibits it at all times under S4.4.1 [8][12]
Is MOTS-c an approved drug?
No. FDA's July 2026 review found no USP or National Formulary monograph, no European or Japanese pharmacopeia listing and no EMA-authorised product [1]. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 [1][9].
Federal compounding status
FDA says state-licensed physicians and pharmacists may compound only with bulk substances that comply with a USP or National Formulary monograph, are components of FDA-approved drugs, or appear on FDA's bulks list, and that the substance must come with a valid certificate of analysis and be made by an FDA-registered establishment [4]. MOTS-c has no USP or National Formulary monograph, is not a component of an FDA-approved drug, and is not on the bulks list [1][4]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, or on FDA's outsourcing facility list, updated March 21, 2025 [2][3][4].
MOTS-c is listed in FDA's 'nominated but withdrawn' table of bulk substances that may present significant safety risks. That table holds substances previously in category 2 whose nominators withdrew them, and removal from category 2 was not a finding that the substance is safe [7]. FDA's stated concerns were that it 'has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration' and that injectable peptides may pose an immunogenicity risk [7]. FDA also states that compounded drugs are not FDA-approved, meaning it does not verify their safety, effectiveness or quality before they are marketed [10]. State boards of pharmacy generally hold primary responsibility for day-to-day oversight of state-licensed pharmacies [10].
Questions worth asking
What changed in 2026
FDA staff proposed in July 2026 that neither the free base nor the acetate be added to the bulks list, citing poor characterisation, unknown compounding use, no human safety or effectiveness data, no animal toxicity studies, and existing approved treatments for obesity and osteoporosis [1]. The Pharmacy Compounding Advisory Committee voted in favour of adding it on July 23, 2026, against staff's recommendation; that vote is advice only and listing takes formal rulemaking [11][5].
HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192; publication scheduled October 30, 2026, with comments due two weeks after publication), naming MOTS-c among six peptides and covering the acetate form given by subcutaneous or intramuscular injection [5]. Under it HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician that compounds it when conditions such as a single active ingredient, a patient-specific prescription, and an FDA-registered manufacturer with a certificate of analysis are met [5][6]. The notice says it 'does not establish any rights for any person and is not binding on HHS or the public' [5].
What is known about human use
FDA found no published study in which MOTS-c was given to a person, and there is no approved dose; the nominated products were 5 mg and 10 mg subcutaneous injections [1]. The reported metabolic effects, such as less weight gain on a high-fat diet, come from mouse studies [9], and FDA found no pharmacokinetic data in humans [1]. WADA lists MOTS-c in S4.4.1 as an AMPK activator, prohibited at all times [8][12].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is MOTS-c legal in Texas?
Can a Texas doctor prescribe MOTS-c?
Does the HHS policy make MOTS-c legal?
References
Show all 12 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Compounding and the FDA: Questions and Answers | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.